FDA expands EUA for Lilly’s Covid-19 drug to include kids below 12 years
The expanded EUA was based on safety and efficacy data of paediatric and infant patients in Phase 2/3…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Dec 21
The expanded EUA was based on safety and efficacy data of paediatric and infant patients in Phase 2/3…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 Dec 21
UCB will receive an upfront payment of $150m and is eligible to receive further milestone payments worth a…
03 Dec 21
Sotrovimab showed activity against mutations of the new Omicron variant (B.1.1.529), according to preclinical data published in bioRxiv
02 Dec 21
Kyprolis in combination with Darzalex Faspro and dexamethasone expands the options for the treatment of relapsed/refractory multiple myeloma
02 Dec 21
Origimm is engaged in discovering virulent skin microbiome components and antigens from bacteria that cause skin disease, including…
01 Dec 21
According to the British drugmaker, Lynparza is the first medicine targeting BRCA mutations that showed clinical benefit in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Dec 21
NKT2152 is a small molecule therapy that inhibits HIF2α, in combination with palbociclib and sasanlimab to treat advanced…
30 Nov 21
The EC approvals for Keytruda plus Lenvima are based on results from CLEAR/KEYNOTE-581 trial and Phase 3 KEYNOTE-775/Study…
29 Nov 21
The partnership is expected to result in the manufacturing of an estimated 80 million doses of the plasmid…
26 Nov 21
If approved, Comirnaty becomes the first Covid-19 vaccine authorised in the EU in the five to 11 years…